SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million
Source
33 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million
Patent protection spans North America, Europe & Asia-Pacific Rim
Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027
Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and
Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of…
Provides Corporate Update
Company Delivers 24% Q3 Revenue Growth and Returns to Positive Operating Income
-First Quarter Revenue Increased 27% Year-over-Year to $5.4 Million; Revenue Plus Interest Income of $5.9 Million*-
First quarter revenue rises 9.3% to $16.4 million; GAAP net income of $0.16 million compared with a net loss in the prior-year period
FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS)
~ Third Quarter Revenue of $96.6 Million, Up 290% YoY ~
– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved…
and Business Updates